Foghorn Therapeutics Says Clinical Data From Phase 1 Study of FHD-286, A Novel BRG1/BRM Inhibitor, In Patients With Advanced Hematologic Malignancies, To Be Presented at American Society of Hematology Annual Meeting
Author: Benzinga Newsdesk | December 01, 2023 08:06am